The emerging role and targetability of the TCA cycle in cancer metabolism
Open accessThe DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Abstract
The tricarboxylic acid (TCA) cycle is a central route for oxidative phosphorylation in cells, and fulfills their bioenergetic, biosynthetic, and redox balance requirements. Despite early dogma that cancer cells bypass the TCA cycle and primarily utilize aerobic glycolysis, emerging evidence demonstrates that certain cancer cells, especially those with deregulated oncogene and tumor suppressor expression, rely heavily on the TCA cycle for energy production and macromolecule synthesis. As the field progresses, the importance of aberrant TCA cycle function in tumorigenesis and the potentials of applying small molecule inhibitors to perturb the enhanced cycle function for cancer treatment start to evolve. In this review, we summarize current knowledge about the fuels feeding the cycle, effects of oncogenes and tumor suppressors on fuel and cycle usage, common genetic alterations and deregulation of cycle enzymes, and potential therapeutic opportunities for targeting the TCA cycle in cancer cells. With the application of advanced technology and in vivo model organism studies, it is our hope that studies of this previously overlooked biochemical hub will provide fresh insights into cancer metabolism and tumorigenesis, subsequently revealing vulnerabilities for therapeutic interventions in various cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 2×
“Indeed, various types of cancer cells increase their glucose uptake and preferentially utilize glucose through aerobic glycolysis (Gillies and Gatenby, 2007; Pavlova and Thompson, 2016).”
BackgroundAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Unlike FH and SDH, mutations in IDH1 and 2 are somatic heterozygous missense mutations that occur primarily at the active arginine residues that are critical for isocitrate binding (IDH1: R132; IDH2: R172, R140; Table 1) (Parsons et al., 2008; Dang et al., 2009; Mardis et al., 2009; Yan et al., 2009).”
BackgroundIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154 · cited 3×
“On the other hand, IDH1/2 missense mutations render the enzymes acquiring neomorphic activity that can convert α-KG to 2-HG (Dang et al., 2009).”
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 12×
“While CPI-613 stimulates PDK to phosphorylate and inactivate PDH (Zachar et al., 2011), CPI613 can also induce a burst of mitochondria ROS through acting on DLD (the E3 component of KGDHC) and suppression of the E2 subunit of KGDHC, DLST (Stuart et al., 2014).”
BackgroundInfluentialHypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation
Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140 · cited 2×
“MYC-dependent cancer cells can utilize either GLUD or aminotransferases to convert glutamine to α-KG for the TCA cycle (Wise et al., 2008; Wang et al., 2011).”
BackgroundGao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“Mutations predisposing patients to MCUL or HLRCC occur across the gene and include missense, frameshift, nonsense and large deletions at the FH locus (Table 1) (Bensaad et al., 2006).”
BackgroundWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001 · cited 13×
“This article is an open access publication P ro te in & C e ll (GLS) to yield glutamate, which subsequently is either dehydrogenated by glutamate dehydrogenase (GLUD) to form αKG or functions as a co-substrate for the transaminases, glutamate oxaloacetate transaminase and glutamate pyruvate transaminase to form alanin…”
BackgroundInfluentialReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · cited 1×
“Under hypoxia conditions, glutamine largely fuels the TCA cycle in the form of α-KG to promote reductive carboxylation that produces citrate for lipogenesis (Wise et al., 2008; Metallo et al., 2011; Gameiro et al., 2013).”
BackgroundRAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“RAS plays a critical role in activating scavenging pathways in certain types of tumors and promotes nutrient uptake through both the extracellular and intracellular sources (Pylayeva-Gupta et al., 2011; Stephen et al., 2014).”
BackgroundMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“Mutations in SDHA, SDHB, SDHC, SDHD and SDH assembly factor 2 (SDHAF2) have been identified in hereditary paragangliomas (hPGLs) and pheochromocytomas (PCCs) (Table 1) (Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001; Baysal et al., 2002; Hao et al., 2009; Bayley et al., 2010; Burnichon et al., 2010…”
BackgroundThe Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635 · cited 1×
“Heterozygous mutations in FH predispose patients to multiple cutaneous and uterine leiomyomas (MCUL), as well as hereditary leiomyomatosis and renal cell cancer (HLRCC) (Table 1) (Launonen et al., 2001; Tomlinson et al., 2002).”
BackgroundReflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×
“The proto-oncogene MYC controls a wide range of cellular processes, including cell proliferation, metabolism, cellular differentiation and genomic instability, and is a dominant driver of tumor transformation and progression (Meyer and Penn, 2008).”
BackgroundCancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505 · cited 1×
“Cancer cells often escape treatment through compensatory pathways (Obre and Rossignol, 2015; Zugazagoitia et al., 2016), and the metabolic properties of cancer cells are often context-dependent (Yuneva et al., 2012; Kishton et al., 2016; Martinez-Outschoorn et al., 2017).”
BackgroundQ's next: the diverse functions of glutamine in metabolism, cell biology and cancer
DeBerardinis, R. J., & Cheng, T. (2010) · Oncogene · doi:10.1038/onc.2009.358 · Cited by 1,365
Reductive carboxylation supports growth in tumour cells with defective mitochondria
Mullen, A. R., Wheaton, W. W., Jin, E. S., Chen, P.-H., Sullivan, L. B., Cheng, T., Yang, Y., Linehan, W. M., Chandel, N. S., & DeBerardinis, R. J. (2012) · Nature · doi:10.1038/nature10642 · Cited by 1,328 · cited 14×
“Finally, mutations in TCA cycle gene IDH2 provide a unique opportunity for therapeutic intervention.”
BackgroundInfluentialActivated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323
Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.
Reitzer, L. J., Wice, B. M., & Kennell, D. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30124-2 · Cited by 1,240
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Transcriptional regulation and transformation by Myc proteins
Adhikary, S., & Eilers, M. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1703 · Cited by 1,131
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Zhang, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.009 · Cited by 1,095
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 1×
“Mutations in SDHA, SDHB, SDHC, SDHD and SDH assembly factor 2 (SDHAF2) have been identified in hereditary paragangliomas (hPGLs) and pheochromocytomas (PCCs) (Table 1) (Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001; Baysal et al., 2002; Hao et al., 2009; Bayley et al., 2010; Burnichon et al., 2010…”
BackgroundP53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
A general introduction to the biochemistry of mitochondrial fatty acid β‐oxidation
Houten, S. M., & Wanders, R. J. A. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9061-2 · Cited by 1,020
Current Challenges in Cancer Treatment
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.026 · Cited by 926
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893
Kamphorst, J. J., Nofal, M., Commisso, C., Hackett, S. R., Lu, W., Grabocka, E., Vander Heiden, M. G., Miller, G., Drebin, J. A., Bar-Sagi, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2211 · Cited by 893
Mutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 1×
“Mutations in SDHA, SDHB, SDHC, SDHD and SDH assembly factor 2 (SDHAF2) have been identified in hereditary paragangliomas (hPGLs) and pheochromocytomas (PCCs) (Table 1) (Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001; Baysal et al., 2002; Hao et al., 2009; Bayley et al., 2010; Burnichon et al., 2010…”
BackgroundPollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 818
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 2×
“The most frequently mutated RAS subfamily genes in cancer are KRAS, NRAS, and HRAS, which serve as intercellular signaling molecules to transduce extracellular signaling from receptor tyrosine kinase to downstream effectors (PylayevaGupta et al., 2011; Stephen et al., 2014).”
BackgroundCitric Acid Cycle and Role of its Intermediates in Metabolism
Akram, M. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9750-1 · Cited by 741
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
SDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma
Hao, H.-X., Khalimonchuk, O., Schraders, M., Dephoure, N., Bayley, J.-P., Kunst, H., Devilee, P., Cremers, C. W. R. J., Schiffman, J. D., Bentz, B. G., et al. (2009) · Science · doi:10.1126/science.1175689 · Cited by 702 · cited 1×
“Mutations in SDHA, SDHB, SDHC, SDHD and SDH assembly factor 2 (SDHAF2) have been identified in hereditary paragangliomas (hPGLs) and pheochromocytomas (PCCs) (Table 1) (Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001; Baysal et al., 2002; Hao et al., 2009; Bayley et al., 2010; Burnichon et al., 2010…”
BackgroundInherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669 · cited 1×
“Heterozygous mutations in FH predispose patients to multiple cutaneous and uterine leiomyomas (MCUL), as well as hereditary leiomyomatosis and renal cell cancer (HLRCC) (Table 1) (Launonen et al., 2001; Tomlinson et al., 2002).”
BackgroundSDHA is a tumor suppressor gene causing paraganglioma
Burnichon, N., Brière, J.-J., Libé, R., Vescovo, L., Rivière, J., Tissier, F., Jouanno, E., Jeunemaitre, X., Bénit, P., Tzagoloff, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq206 · Cited by 650
Mayers, J. R., Wu, C., Clish, C. B., Kraft, P., Torrence, M. E., Fiske, B. P., Yuan, C., Bao, Y., Townsend, M. K., Tworoger, S. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3686 · Cited by 649
Glycolytic Enzymes Can Modulate Cellular Life Span
Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., & Beach, D. (2005) · Cancer Research · doi:10.1158/0008-5472.177.65.1 · Cited by 647 · cited 1×
“P53 acts to suppress glycolysis by directly downregulating glucose transporters (GLUT1 and GLUT4) and indirectly inhibiting the activity of glycolytic enzymes, phosphofructokinase 1 (PFK1) and phosphoglycerate mutase (Kondoh et al., 2005; Bensaad et al., 2006, 2009; Zhang et al., 2013).”
BackgroundThe metabolic profile of tumors depends on both the responsible genetic lesion and tissue type
Yuneva, M. O., Fan, T. W. M., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., Matés, J. M., Alonso, F. J., Wang, C., Seo, Y., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.015 · Cited by 639
Toro, J. R., Nickerson, M. L., Wei, M.-H., Warren, M. B., Glenn, G. M., Turner, M. L., Stewart, L., Duray, P., Tourre, O., Sharma, N., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376435 · Cited by 634
Janeway, K. A., Kim, S. Y., Lodish, M., Nosé, V., Rustin, P., Gaal, J., Dahia, P. L. M., Liegl, B., Ball, E. R., Raygada, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009199108 · Cited by 628
Mitochondrial tumour suppressors: a genetic and biochemical update
Gottlieb, E., & Tomlinson, I. P. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1737 · Cited by 621
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Cairns, R. A., Iqbal, J., Lemonnier, F., Kucuk, C., de Leval, L., Jais, J.-P., Parrens, M., Martin, A., Xerri, L., Brousset, P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391748 · Cited by 509
Pasini, B., McWhinney, S. R., Bei, T., Matyakhina, L., Stergiopoulos, S., Muchow, M., Boikos, S. A., Ferrando, B., Pacak, K., Assie, G., et al. (2008) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201904 · Cited by 487
Pyruvate carboxylase is required for glutamine-independent growth of tumor cells
Cheng, T., Sudderth, J., Yang, C., Mullen, A. R., Jin, E. S., Matés, J. M., & DeBerardinis, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016627108 · Cited by 475
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1034 · Cited by 471 · cited 1×
“IDH1/2 mutations occur frequently in low-grade glioma and secondary glioblastoma (∼80%), but can also occur in acute myeloid leukemia (20%), angioimmunoblastic T-cell lymphomas (20%), and rarely in other malignancies such as thyroid, colorectal, and prostate cancer (Table 1) (Kang et al., 2009; Yen et al., 2010; Ghiam…”
BackgroundHypoxia-inducible factors: central regulators of the tumor phenotype
Gordan, J. D., & Simon, M. C. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.006 · Cited by 453
Tumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · cited 1×
“P53 acts to suppress glycolysis by directly downregulating glucose transporters (GLUT1 and GLUT4) and indirectly inhibiting the activity of glycolytic enzymes, phosphofructokinase 1 (PFK1) and phosphoglycerate mutase (Kondoh et al., 2005; Bensaad et al., 2006, 2009; Zhang et al., 2013).”
BackgroundExtreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect
Zhang, C., Lin, M., Wu, R., Wang, X., Yang, B., Levine, A. J., Hu, W., & Feng, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113884108 · Cited by 431
ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer
Migita, T., Narita, T., Nomura, K., Miyagi, E., Inazuka, F., Matsuura, M., Ushijima, M., Mashima, T., Seimiya, H., Satoh, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1235 · Cited by 403 · cited 2×
“Acetyl-CoA is the substrate for both the fatty acid synthesis pathway and the TCA cycle, making lipogenesis an important convergence point for TCA cycle flux and cellular biosynthesis (Migita et al., 2008).”
BackgroundThe x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399
Bardella, C., Pollard, P. J., & Tomlinson, I. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.07.003 · Cited by 395
Abbas, S., Lugthart, S., Kavelaars, F. G., Schelen, A., Koenders, J. E., Zeilemaker, A., van Putten, W. J. L., Rijneveld, A. W., Löwenberg, B., & Valk, P. J. M. (2010) · Blood · doi:10.1182/blood-2009-11-250878 · Cited by 393
A role for mitochondrial enzymes in inherited neoplasia and beyond
Eng, C., Kiuru, M., Fernandez, M. J., & Aaltonen, L. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1013 · Cited by 392
Vanharanta, S., Buchta, M., McWhinney, S. R., Virta, S. K., Peçzkowska, M., Morrison, C. D., Lehtonen, R., Januszewicz, A., Järvinen, H., Juhola, M., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/381054 · Cited by 389
Jacque, N., Ronchetti, A. M., Larrue, C., Meunier, G., Birsen, R., Willems, L., Saland, E., Decroocq, J., Maciel, T. T., Lambert, M., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621870 · Cited by 387
Swinnen, J. V., Roskams, T., Joniau, S., Van Poppel, H., Oyen, R., Baert, L., Heyns, W., & Verhoeven, G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10127 · Cited by 381
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J.-L., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 373
Modulation of intracellular ROS levels by TIGAR controls autophagy
Bensaad, K., Cheung, E. C., & Vousden, K. H. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.242 · Cited by 360
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., DiNardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. (2017) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 350
Interorgan Amino Acid Transport and its Regulation
Brosnan, J. T. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.6.2068s · Cited by 347
Germline SDHB Mutations and Familial Renal Cell Carcinoma
Ricketts, C., Woodward, E. R., Killick, P., Morris, M. R., Astuti, D., Latif, F., & Maher, E. R. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn254 · Cited by 342
Baysal, B. E., Willett-Brozick, J. E., Lawrence, E. C., Drovdlic, C. M., Savul, S. A., McLeod, D. R., Yee, H. A., Brackmann, D. E., Slattery, W. H., Myers, E. N., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.3.178 · Cited by 339
Chen, J.-Q., & Russo, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.004 · Cited by 327
Gameiro, P. A., Yang, J., Metelo, A. M., Pérez-Carro, R., Baker, R., Wang, Z., Arreola, A., Rathmell, W. K., Olumi, A., López-Larrubia, P., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.002 · Cited by 325 · cited 1×
“Under hypoxia conditions, glutamine largely fuels the TCA cycle in the form of α-KG to promote reductive carboxylation that produces citrate for lipogenesis (Wise et al., 2008; Metallo et al., 2011; Gameiro et al., 2013).”
BackgroundEagle, H. (1955) · The Journal of Experimental Medicine · doi:10.1084/jem.102.5.595 · Cited by 323 · cited 2×
“While glucose provides the main source of pyruvate entering the TCA cycle in normal cells, cancer cells often shunt glucose away from the TCA cycle for catabolism through anaerobic glycolysis, and thus are more dependent on glutamine and fatty acids to replenish TCA cycle intermediates (Eagle, 1955).”
BackgroundMutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Kang, M. R., Kim, M. S., Oh, J. E., Kim, Y. R., Song, S. Y., Seo, S. I., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24379 · Cited by 313
Wei, M.-H., Toure, O., Glenn, G. M., Pithukpakorn, M., Neckers, L., Stolle, C., Choyke, P., Grubb, R., Middelton, L., Turner, M. L., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.033506 · Cited by 313
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. (2016) · Nature · doi:10.1038/nature16967 · Cited by 313
The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling
Sullivan, L. B., Martinez-Garcia, E., Nguyen, H., Mullen, A. R., Dufour, E., Sudarshan, S., Licht, J. D., Deberardinis, R. J., & Chandel, N. S. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.003 · Cited by 304
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R. (2010) · Oncogene · doi:10.1038/onc.2010.444 · Cited by 296
Inhibition of leukemias in man by L-asparaginase.
Oettgen, H. F., Lj, O., Boyse, E. A., Ha, C., Fs, P., Clarkson, B., Tallal, L., Leeper, R. D., Mk, S., & Kim, J. H. (1967) · PubMed · Cited by 284
Transformation of Rat Fibroblasts by FSV Rapidly Increases Glucose Transporter Gene Transcription
Birnbaum, M. J., Haspel, H. C., & Rosen, O. M. (1987) · Science · doi:10.1126/science.3029870 · Cited by 281
Grassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0772-t · Cited by 280
Korpershoek, E., Favier, J., Gaal, J., Burnichon, N., van Gessel, B., Oudijk, L., Badoual, C., Gadessaud, N., Venisse, A., Bayley, J.-P., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1043 · Cited by 277
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma
Bayley, J.-P., Kunst, H. P., Cascon, A., Sampietro, M. L., Gaal, J., Korpershoek, E., Hinojar-Gutierrez, A., Timmers, H. J., Hoefsloot, L. H., Hermsen, M. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70007-3 · Cited by 276
Gimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Signaling in Control of Cell Growth and Metabolism
Ward, P. S., & Thompson, C. B. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006783 · Cited by 270
Pathania, D., Millard, M., & Neamati, N. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.010 · Cited by 263
Kishton, R. J., Barnes, C. E., Nichols, A. G., Cohen, S., Gerriets, V. A., Siska, P. J., Macintyre, A. N., Goraksha-Hicks, P., de Cubas, A. A., Liu, T., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.008 · Cited by 260
Gibson, G. E., Starkov, A., Blass, J. P., Ratan, R. R., & Beal, M. F. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.010 · Cited by 256
Kosmider, O., Gelsi-Boyer, V, Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Hunault-Berger, M., Slama, B., Vey, N., Lacombe, C., et al. (2010) · Leukemia · doi:10.1038/leu.2010.52 · Cited by 247
p53 Negatively Regulates Transcription of the Pyruvate Dehydrogenase Kinase Pdk2
Contractor, T., & Harris, C. R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1215 · Cited by 245
Metabolism and action of amino acid analog anti-cancer agents
Ahluwalia, G. S., Grem, J. L., Hao, Z., & Cooney, D. A. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90094-i · Cited by 240
Familial Gastrointestinal Stromal Tumors and Germ-Line Mutations
McWhinney, S. R., Pasini, B., & Stratakis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071191 · Cited by 224
Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?
Gillies, R. J., & Gatenby, R. A. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9085-y · Cited by 219
Zachar, Z., Marecek, J., Maturo, C., Gupta, S., Stuart, S. D., Howell, K., Schauble, A., Lem, J., Piramzadian, A., Karnik, S., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0785-8 · Cited by 216
Chan, W. K., Lorenzi, P. L., Anishkin, A., Purwaha, P., Rogers, D. M., Sukharev, S., Rempe, S. B., & Weinstein, J. N. (2014) · Blood · doi:10.1182/blood-2013-10-535112 · Cited by 210
Smit, D., Mensenkamp, A., Badeloe, S., Breuning, M., Simon, M., Van Spaendonck, K., Aalfs, C., Post, J., Shanley, S., Krapels, I., et al. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01486.x · Cited by 195
Miettinen, M., Killian, J. K., Wang, Z.-F., Lasota, J., Lau, C., Jones, L., Walker, R., Pineda, M., Zhu, Y. J., Kim, S. Y., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182671178 · Cited by 195
Neumann, H. P. H., Erlic, Z., Boedeker, C. C., Rybicki, L. A., Robledo, M., Hermsen, M., Schiavi, F., Falcioni, M., Kwok, P., Bauters, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4057 · Cited by 194
Aspuria, P.-J. P., Lunt, S. Y., Väremo, L., Vergnes, L., Gozo, M., Beach, J. A., Salumbides, B., Reue, K., Wiedemeyer, W. R., Nielsen, J., et al. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-21 · Cited by 185
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
Pardanani, A., Lasho, T. L., Finke, C. M., Mai, M., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.77 · Cited by 184
Stuart, S. D., Schauble, A., Gupta, S., Kennedy, A. D., Keppler, B. R., Bingham, P. M., & Zachar, Z. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-4 · Cited by 183
Impact of MYC in regulation of tumor cell metabolism
Wahlström, T., & Arsenian Henriksson, M. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.07.004 · Cited by 178
Xin, M., Qiao, Z., Li, J., Liu, J., Song, S., Zhao, X., Miao, P., Tang, T., Wang, L., Liu, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10020 · Cited by 177
Bolzoni, M., Chiu, M., Accardi, F., Vescovini, R., Airoldi, I., Storti, P., Todoerti, K., Agnelli, L., Missale, G., Andreoli, R., et al. (2016) · Blood · doi:10.1182/blood-2016-01-690743 · Cited by 176
Metabolic remodeling of white adipose tissue in obesity
Cummins, T. D., Holden, C. R., Sansbury, B. E., Gibb, A. A., Shah, J., Zafar, N., Tang, Y., Hellmann, J., Rai, S. N., Spite, M., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00271.2013 · Cited by 171
Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues
Singh, K. K., Desouki, M. M., Franklin, R. B., & Costello, L. C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-14 · Cited by 169
Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) – A review
Miettinen, M., & Lasota, J. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.05.033 · Cited by 168
Taschner, P. E. M., Jansen, J. C., Baysal, B. E., Bosch, A., Rosenberg, E. H., Bröcker‐Vriends, A. H. J. T., van der Mey, A. G. L., van Ommen, G. B., Cornelisse, C. J., & Devilee, P. (2001) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.1144 · Cited by 165
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Shi, J., Sun, B., Shi, W., Zuo, H., Cui, D., Ni, L., & Chen, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2644-z · Cited by 163
Gardie, B., Remenieras, A., Kattygnarath, D., Bombled, J., Lefèvre, S.-H., Perrier-Trudova, V., Rustin, P., Barrois, M., Slama, A., Avril, M., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2010.085068 · Cited by 160
Lin, C.-C., Cheng, T.-L., Tsai, W.-H., Tsai, H.-J., Hu, K.-H., Chang, H.-C., Yeh, C.-W., Chen, Y.-C., Liao, C.-C., & Chang, W.-T. (2012) · Scientific Reports · doi:10.1038/srep00785 · Cited by 155
Pantaleo, M. A., Astolfi, A., Indio, V., Moore, R., Thiessen, N., Heinrich, M. C., Gnocchi, C., Santini, D., Catena, F., Formica, S., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr130 · Cited by 152
Wang, M., Wu, H., Fu, G., Zhang, H., Zhou, X., Tang, L., Dong, L., Qin, C., Huang, S., Zhao, L., et al. (2016) · Hepatology · doi:10.1002/hep.28415 · Cited by 152
Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome
Hoque, M. O., Kim, M. S., Ostrow, K. L., Liu, J., Wisman, G. B. A., Park, H. L., Poeta, M. L., Jerónimo, C., Henrique, R., Lendvai, Á., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5913 · Cited by 149
Adult Leydig Cell Tumors of the Testis Caused by Germline Fumarate Hydratase Mutations
Carvajal-Carmona, L. G., Alam, N. A., Pollard, P. J., Jones, A. M., Barclay, E., Wortham, N., Pignatelli, M., Freeman, A., Pomplun, S., Ellis, I., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0183 · Cited by 145
Obre, E., & Rossignol, R. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.12.008 · Cited by 137
Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human
Rustin, P., Bourgeron, T., Parfait, B., Chretien, D., Munnich, A., & Rötig, A. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00035-5 · Cited by 137
Regulation of fatty acid synthase gene expression: an approach for reducing fat accumulation
Clarke, S. D. (1993) · Journal of Animal Science · doi:10.2527/1993.7171957x · Cited by 134
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 132
Murugan, A. K., Bojdani, E., & Xing, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.095 · Cited by 131
Lemonnier, F., Cairns, R. A., Inoue, S., Li, W. Y., Dupuy, A., Broutin, S., Martin, N., Fataccioli, V., Pelletier, R., Wakeham, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617929114 · Cited by 121
Familial SDHA Mutation Associated With Pituitary Adenoma and Pheochromocytoma/Paraganglioma
Dwight, T., Mann, K., Benn, D. E., Robinson, B. G., McKelvie, P. A., Gill, A. J., Winship, I., & Clifton-Bligh, R. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1400 · Cited by 118
Pardee, T. S., Lee, K., Luddy, J., Maturo, C., Rodriguez, R., Isom, S., Miller, L. D., Stadelman, K. M., Levitan, D., Hurd, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1019 · Cited by 117
Evenepoel, L., Papathomas, T. G., Krol, N. M. G., Korpershoek, E., de Krijger, R. R., Persu, A., & Dinjens, W. N. M. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.162 · Cited by 115
Glutamine Addiction In Gliomas
Márquez, J., Alonso, F. J., Matés, J. M., Segura, J. A., Martín‐Rufián, M., & Campos-Sandoval, J. A. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2212-1 · Cited by 115
Glutaminase activity determines cytotoxicity of l-asparaginases on most leukemia cell lines
Parmentier, J. H., Maggi, M., Tarasco, E., Scotti, C., Avramis, V. I., & Mittelman, S. D. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.04.008 · Cited by 114
Enhanced Citrate Synthase Activity in Human Pancreatic Cancer
Schlichtholz, B., Turyn, J., Goyke, E., Biernacki, M., Jaśkiewicz, K., Śledziński, Z., & Świerczyński, J. (2005) · Pancreas · doi:10.1097/01.mpa.0000153326.69816.7d · Cited by 111
c-Myc Programs Fatty Acid Metabolism and Dictates Acetyl-CoA Abundance and Fate
Edmunds, L. R., Sharma, L., Kang, A., Lu, J., Vockley, J., Basu, S., Uppala, R., Goetzman, E. S., Beck, M. E., Scott, D., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.580662 · Cited by 109
Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation
Pęczkowska, M., Cascón, A., Prejbisz, A., Kubaszek, A., Ćwikła, J. B., Furmanek, M. I., Erlic, Z., Eng, C., Januszewicz, A., & Neumann, H. P. H. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0726 · Cited by 108
Rodman, S. N., Spence, J., Ronnfeldt, T. J., Zhu, Y., Solst, S. R., O'Neill, R. A., Allen, B. G., Guan, X., Spitz, D. R., & Fath, M. A. (2016) · Radiation Research · doi:10.1667/rr14463.1 · Cited by 108
Citrate Synthase Expression Affects Tumor Phenotype and Drug Resistance in Human Ovarian Carcinoma
Chen, L., Liu, T., Zhou, J., Wang, Y., Wang, X., Di, W. J., & Zhang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115708 · Cited by 104
Yang, Y., Lane, A. N., Ricketts, C. J., Sourbier, C., Wei, M.-H., Shuch, B., Pike, L., Wu, M., Rouault, T. A., Boros, L. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072179 · Cited by 103
Hoekstra, A. S., de Graaff, M. A., Briaire-de Bruijn, I. H., Ras, C., Seifar, R. M., van Minderhout, I., Cornelisse, C. J., Hogendoorn, P. C. W., Breuning, M. H., Suijker, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6091 · Cited by 99
Genetic screening for pheochromocytoma: should SDHC gene analysis be included?: Figure 1
Mannelli, M., Ercolino, T., Giachè, V, Simi, L., Cirami, C., & Parenti, G. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.051045 · Cited by 95
Douwes Dekker, P., Hogendoorn, P., Kuipers‐Dijkshoorn, N., Prins, F., van Duinen, S., Taschner, P., van der Mey, A., & Cornelisse, C. (2003) · The Journal of Pathology · doi:10.1002/path.1461 · Cited by 94
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors
Oudijk, L., Gaal, J., Korpershoek, E., van Nederveen, F. H., Kelly, L., Schiavon, G., Verweij, J., Mathijssen, R. H. J., den Bakker, M. A., Oldenburg, R. A., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.186 · Cited by 90
Gao, C., Shen, Y., Jin, F., Miao, Y., & Qiu, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154576 · Cited by 88
Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30‐year‐old mystery
Schimke, R. N., Collins, D. L., & Stolle, C. A. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33384 · Cited by 84
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas
Hemerly, J. P., Bastos, A. U., & Cerutti, J. M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0473 · Cited by 82
Dannenberg, H., Dinjens, W. N. M., Abbou, M., van Urk, H., Pauw, B. K. H., Mouwen, D., Mooi, W. J., & de Krijger, R. R. (2002) · PubMed · Cited by 81
Autophagy promotes Braf V600E -driven lung tumorigenesis by preserving mitochondrial metabolism
Strohecker, A. M., & White, E. (2014) · Autophagy · doi:10.4161/auto.27320 · Cited by 80
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy
Pfaffenroth, E. C., & Linehan, W. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.779 · Cited by 80
ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis
Wang, D., Yin, L., Wei, J., Yang, Z.-X., & Jiang, G. (2017) · Tumor Biology · doi:10.1177/1010428317698338 · Cited by 78
Menéndez, J. A., Ropero, S., Mehmi, I., Atlas, E., Colomer, R., & Lupu, R. (2004) · PubMed · Cited by 77
Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH
Allen, E. L., Ulanet, D., Pirman, D. A., Mahoney, C. E., Coco, J., Si, Y., Chen, Y., Huang, L., Ren, J., Choe, S. E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.052 · Cited by 74
Belinsky, M. G., Rink, L. A., Flieder, D. B., Jahromi, M. S., Schiffman, J. D., Godwin, A. K., & von Mehren, M. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22023 · Cited by 72
IDH mutation status in prostate cancer
Ghiam, A. F., Cairns, R. A., Thoms, J., Pra, A. D., Ahmed, O., Meng, A. X., Mak, T. W., & Bristow, R. G. (2011) · Oncogene · doi:10.1038/onc.2011.546 · Cited by 71
Pharmacologic Unmasking of Epigenetically Silenced Genes in Breast Cancer
Ostrow, K. L., Park, H. L., Hoque, M. O., Kim, M. S., Liu, J.-W., Argani, P., Westra, W. H., Criekinge, W. V., & Sidransky, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1304 · Cited by 71
SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors
Italiano, A., Chen, C.-L., Sung, Y., Singer, S., DeMatteo, R. P., LaQuaglia, M. P., Besmer, P., Socci, N. D., & Antonescu, C. R. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-408 · Cited by 66
Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors
Belinsky, M. G., Rink, L., & von Mehren, M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00117 · Cited by 66
Shitara, K., Doi, T., Nagano, O., Fukutani, M., Hasegawa, H., Nomura, S., Sato, A., Kuwata, T., Asai, K., Einaga, Y., et al. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0720-y · Cited by 63
Wang, P., Mai, C., Wei, Y.-L., Zhao, J.-J., Hu, Y.-M., Zeng, Z.-L., Yang, J., Lu, W.-H., Xu, R., & Huang, P. (2013) · Medical Oncology · doi:10.1007/s12032-013-0552-5 · Cited by 62
The Succinated Proteome of FH-Mutant Tumours
Yang, M. H., Ternette, N., Su, H., Dabiri, R., Kessler, B. M., Adam, J., Teh, B. T., & Pollard, P. J. (2014) · Metabolites · doi:10.3390/metabo4030640 · Cited by 62
Pusch, S., Sahm, F., Meyer, J., Mittelbronn, M. G. A., Hartmann, C. J., & von Deimling, A. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01127.x · Cited by 62
Lycan, T. W., Pardee, T. S., Petty, W. J., Bonomi, M., Alistar, A., Lamar, Z. S., Isom, S., Chan, M. D., Miller, A. A., & Ruiz, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164244 · Cited by 62
Pituitary Carcinoma in a Patient with an SDHB Mutation
Tufton, N., Roncaroli, F., Hadjidemetriou, I., Dang, M. N., Dénes, J., Guasti, L., Thom, M., Powell, M. P., Baldeweg, S. E., Fersht, N. L., et al. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9474-7 · Cited by 62
The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis
Anderson, N. M., Li, D., Peng, H., Laroche, F., Mansour, M. R., Gjini, E., Aioub, M., Helman, D., Roderick, J. E., Cheng, T., et al. (2016) · Leukemia · doi:10.1038/leu.2016.26 · Cited by 60
Self-citationOvejera, A. A., Houchens, D. P., Catane, R., Sheridan, M. A., & Muggia, F. M. (1979) · PubMed · Cited by 59
Downregulation of OGDHL expression is associated with promoter hypermethylation in colorectal cancer
Fedorova, M., Kudryavtseva, A. V., Lakunina, V. A., Snezhkina, A. V., Волченко, Н. Н., Slavnova, E. N., Данилова, Т. В., Садритдинова, А. Ф., Melnikova, N. V., Белова, А. А., et al. (2015) · Molecular Biology · doi:10.1134/s0026893315040044 · Cited by 55
Snezhkina, A. V., Krasnov, G. S., Zaretsky, A. R., Zhavoronkov, A. A., Nyushko, K. М., Moskalev, A., Karpova, I. Y., Afremova, A. I., Lipatova, A. V., Кочетков, Д. В., et al. (2016) · BMC Genomics · doi:10.1186/s12864-016-3351-5 · Cited by 54
Simi, L., Sestini, R., Ferruzzi, P., Gaglianò, M. S., Gensini, F., Mascalchi, M., Guerrini, L., Pratesi, C., Pinzani, P., Nesi, G., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.030353 · Cited by 51
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase
Ilic, N., Birsoy, K., Aguirre, A. J., Kory, N., Pacold, M. E., Singh, S., Moody, S. E., DeAngelo, J. D., Spardy, N. A., Freinkman, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617922114 · Cited by 51
Baysal, B. E. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000436 · Cited by 50
Novel Therapeutic Targets of Tumor Metabolism
Kishton, R. J., & Rathmell, J. C. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000099 · Cited by 50
Zantour, B., Guilhaume, B., Tissier, F., Louvel, A., Jeunemaître, X., Gimenez‐Roqueplo, A., & BERTAGNA, X. Y. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510433 · Cited by 49
Lipid Synthesis Is a Metabolic Liability of Non–Small Cell Lung Cancer
Svensson, R. U., & Shaw, R. J. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030874 · Cited by 44
Jiang, Q., Zhang, Y., Zhou, Y., Hou, Y., Wang, J., Li, J., Li, M., Tong, H., & Lu, W. (2015) · PubMed · Cited by 41
Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma
Ylisaukko‐oja, S. K., Cybulski, C., Lehtonen, R., Kiuru, M. H., Trubicka, J., Szymañska, A., Szymańska-Pasternak, J., Dyrskjøt, L., Bützow, R. C., Orntoft, T. F., et al. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201630 · Cited by 35
Paik, J. Y., Toon, C. W., Benn, D. E., High, H. A., Hasovitz, C., Pavlakis, N., Clifton-Bligh, R. J., & Gill, A. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2647 · Cited by 35
Mutation Analysis of Isocitrate Dehydrogenase in Acute Lymphoblastic Leukemia
Zhang, Y., Wei, H., Tang, K., Lin, D., Zhang, C., Mi, Y., Wang, L., Wang, C., Wang, M., & Wang, J. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0323 · Cited by 33
Fedorova, M., Кудрявцева, А. В., Lakunina, V. A., Snezhkina, A. V., Волченко, Н. Н., Slavnova, E. N., Данилова, Т. В., Садритдинова, А. Ф., Melnikova, N. V., Белова, А. А., et al. (2015) · Molecular Biology · doi:10.7868/s0026898415040047 · Cited by 33
Griffiths, M., Keast, D. H., Crawford, M. A., Palmer, T. N., & Patrick, G. J. (1993) · International Journal of Biochemistry · doi:10.1016/0020-711x(88)90303-5 · Cited by 30
Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC)
Wong, W., Tan, C. S., Lee, S. C., Yong, Y., Ooi, A. S., Ngeow, J. Y. Y., & Tan, M. H. (2014) · Familial Cancer · doi:10.1007/s10689-014-9703-x · Cited by 23
W43X SDHD mutation in sporadic head and neck paraganglioma.
Galera‐Ruiz, H., González‐Cámpora, R., Rey-Barrera, M., Mayordomo, Á. R., García‐Escudero, A., Fernández-Santos, J. M., DeMiguel, M., & Galera-Davidson, H. (2008) · PubMed · Cited by 23
Hereditary Paraganglioma Due to the SDHD M1I Mutation in a Second Chinese Family: A Founder Effect?
Lee, S. C., Chionh, S. B., Chong, S., & Taschner, P. E. M. (2003) · The Laryngoscope · doi:10.1097/00005537-200306000-00026 · Cited by 22
Deregulation of hexose transporter expression in Caco-2 cells by ras and polyoma middle T oncogenes
Baron-Delage, S., Mahraoui, L., Cadoret, A., Veissière, D., Taillemite, J., Chastre, E., Gespach, C. P., Zweibaum, A., Capeau, J., Brot‐Laroche, E., et al. (1996) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1996.270.2.g314 · Cited by 22
Pillai, S., Gopalan, V., Lo, C. Y., Liew, V., Smith, R. A., & Lam, A. K.-Y. (2016) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2016.12.007 · Cited by 22
Bennedbæk, M., Rossing, M., Rasmussen, Å. K., Gerdes, A., Skytte, A., Jensen, U. B., Nielsen, F. C., & Hansen, T. V. O. (2016) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-016-0053-6 · Cited by 16
Valencia, C. A., López, M. L. R., Barreto, A. Y. C., Rodríguez, E. G., & Díaz, C. E. A. (2016) · Familial Cancer · doi:10.1007/s10689-016-9922-4 · Cited by 14
Mutation screening in a Norwegian cohort with pheochromocytoma
Sjursen, W., Halvorsen, H., Hofsli, E., Bachke, S., Berge, Å., Engebretsen, L. F., Falkmer, S. E., Falkmer, S., & Varhaug, J. E. (2013) · Familial Cancer · doi:10.1007/s10689-013-9608-0 · Cited by 11
Cited by
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
“In the mitochondrion, glutamine is deaminated to glutamate by glutaminase (GLS), later in other deamination reaction, α-ketoglutarate is generated by the enzyme glutamate dehydrogenase (GDH) finally incorporated into TCA cycle to generate malate by fumarase enzyme since α-ketoglutarate is the major anaplerotic source…”
BackgroundMechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
Schiliro, C., & Firestein, B. L. (2021) · Cells · doi:10.3390/cells10051056 · Cited by 615
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“Dysregulation of these enzymes is often observed in various cancers, making them potential therapeutic targets [225, 226].”
BackgroundMetabolomics Reveal Nanoplastic-Induced Mitochondrial Damage in Human Liver and Lung Cells
Lin, S., Zhang, H., Wang, C., Su, X.-L., Song, Y., Wu, P., Yang, Z., Wong, M.-H., Cai, Z., & Zheng, C. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.2c03980 · Cited by 391
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
Metadata
- Authors
- Anderson, N. M., Mucka, P., Kern, J. G., & Feng, H.
- Venue
- Protein & Cell
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-07-26
- Volume
- 9
- Issue
- 2
- Pages
- 216-237
- ISSN
- 1674-800X (ISSN-L)
- 1674-8018
- OpenAlex
- W2738647095
- Cited by
- 556
- References
- 186
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.